12
views
0
recommends
+1 Recommend
1 collections
    0
    shares

      Neuropsychiatric Disease and Treatment (submit here)

      This international, peer-reviewed Open Access journal by Dove Medical Press focuses on all aspects of neuropsychiatric and neurological disorders. Sign up for email alerts here.

      63,741 Monthly downloads/views I 2.989 Impact Factor I 4.5 CiteScore I 1.09 Source Normalized Impact per Paper (SNIP) I 0.744 Scimago Journal & Country Rank (SJR)

      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Assessment of the Impact of Tardive Dyskinesia in Clinical Practice: Consensus Panel Recommendations

      review-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Purpose

          Tardive dyskinesia (TD) is a hyperkinetic movement disorder in which patients experience abnormal involuntary movements that can have profound negative impacts on physical, cognitive, and psychosocial functioning. Use of measures to assess the functional impact of TD in routine clinical practice is lacking. To address this gap, an advisory panel of experts in psychiatry and movement disorder neurology was convened to develop consensus recommendations on assessment of the impact of TD on patients’ functioning that can be used in clinical practice.

          Methods

          An advisory panel provided recommendations using an iterative process, beginning with a narrative literature review regarding current practices for assessing the impact of TD in clinical settings. A detailed summary was generated, and the advisory panel provided comments about the content and answered questions about assessing TD impact in clinical practice. The panelists’ responses were discussed during a virtual meeting held on August 28, 2020. A second meeting on September 25, 2020, focused on developing and refining recommendations for assessment of the impact of TD in clinical practice. At the conclusion of the second meeting, general consensus was reached on all recommendation statements.

          Results

          As part of routine clinical practice, it is imperative to assess the impact of TD on the patient’s life to help guide treatment decisions. Key domains for assessing the overall impact of TD include social, physical, vocational, and psychological functioning and the impact of TD on the underlying psychiatric disorder. Assessment of TD impact should be performed at every patient visit. Impact assessments should include consultation with patients, caregivers, and family members. Shared decision-making to initiate TD treatment should consider impact.

          Conclusion

          The impact of TD should be assessed routinely, including the key domains of social, physical, vocational, and psychological functioning and the impact of TD on the underlying psychiatric disorder.

          Most cited references46

          • Record: found
          • Abstract: not found
          • Article: not found

          Research diagnoses for tardive dyskinesia.

            Bookmark
            • Record: found
            • Abstract: found
            • Article: found
            Is Open Access

            An Update on Tardive Dyskinesia: From Phenomenology to Treatment

            Tardive dyskinesia (TD), characterized by oro-buccal-lingual stereotypy, can manifest in the form of akathisia, dystonia, tics, tremor, chorea, or as a combination of different types of abnormal movements. In addition to movement disorders (including involuntary vocalizations), patients with TD may have a variety of sensory symptoms, such as urge to move (as in akathisia), paresthesias, and pain. TD is a form of tardive syndrome—a group of iatrogenic hyperkinetic and hypokinetic movement disorders caused by dopamine receptor-blocking agents. The pathophysiology of TD remains poorly understood, and treatment of this condition is often challenging. In this update, we provide the most current information on the history, nomenclature, etiology, pathophysiology, epidemiology, phenomenology, differential diagnosis, and treatment of TD.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): a double-blind, randomised, placebo-controlled, phase 3 trial

              Tardive dyskinesia results from exposure to dopamine receptor antagonists, such as typical and atypical antipsychotics. If clinically appropriate, clinicians often manage this disorder by lowering the dose of, or discontinuing, the causative drug. There is a significant unmet need for a treatment option that does not disrupt treatment regimens for underlying psychiatric illnesses. We aimed to assess the efficacy, safety, and tolerability of fixed doses of deutetrabenazine-a novel vesicular monoamine transporter-2 inhibitor-in patients with tardive dyskinesia.
                Bookmark

                Author and article information

                Journal
                Neuropsychiatr Dis Treat
                Neuropsychiatr Dis Treat
                ndt
                neurodist
                Neuropsychiatric Disease and Treatment
                Dove
                1176-6328
                1178-2021
                24 May 2021
                2021
                : 17
                : 1589-1597
                Affiliations
                [1 ]University of Michigan School of Medicine , Ann Arbor, MI, USA
                [2 ]Baylor College of Medicine , Houston, TX, USA
                [3 ]New York Medical College , Valhalla, NY, USA
                [4 ]GeroPsych Associates of Central Texas , Austin, TX, USA
                [5 ]Parkinson’s Disease and Movement Disorders Center of Boca Raton , Boca Raton, FL, USA
                [6 ]Feinstein Institution for Medical Research , Lynbrook, NY, USA
                [7 ]Rocky Mountain Movement Disorders Center , Englewood, CO, USA
                Author notes
                Correspondence: Richard Jackson University of Michigan School of Medicine , 4111 Andover Road, Suite W100, Bloomfield Hills, MI, 48302, USATel +1 248 290 5400Fax +1 248 290 5401 Email richardjackson2000@yahoo.com
                Author information
                http://orcid.org/0000-0002-6098-9266
                http://orcid.org/0000-0002-2628-9442
                Article
                310605
                10.2147/NDT.S310605
                8164384
                34079257
                cdfa9707-bce0-4659-9806-78871cf75c41
                © 2021 Jackson et al.

                This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.php).

                History
                : 11 March 2021
                : 30 April 2021
                Page count
                Figures: 0, References: 47, Pages: 9
                Funding
                Funded by: Teva Pharmaceuticals;
                Preparation of this manuscript was supported by an independent medical grant sponsored by Teva Pharmaceuticals. The sponsor had no involvement in the development of these consensus recommendations or in development of this manuscript.
                Categories
                Review

                Neurology
                hyperkinetic movement,functional domains,diagnosis,treatment
                Neurology
                hyperkinetic movement, functional domains, diagnosis, treatment

                Comments

                Comment on this article